<article>Chinese investment firms <a href="https://www.dealstreetasia.com/?s=Green%20Pine Capital">Green Pine Capital Partners</a> and <a href="https://www.dealstreetasia.com/?s=Lilly%20Asia">Lilly Asia Ventures</a> have backed the $60-million Series A funding round of US- and Shanghai-based non-invasive genetic diagnostic firm <a href="https://www.dealstreetasia.com/?s=Singlera%20Genomics">Singlera Genomics</a>.</article>

Chinese investment firms <a href="https://www.dealstreetasia.com/?s=Green%20Pine Capital">Green Pine Capital Partners</a> and <a href="https://www.dealstreetasia.com/?s=Lilly%20Asia">Lilly Asia Ventures</a> have backed the $60-million Series A funding round of US- and Shanghai-based non-invasive genetic diagnostic firm <a href="https://www.dealstreetasia.com/?s=Singlera%20Genomics">Singlera Genomics</a>.
Green Pine, one of the highest performing VC/PE firms in China, and Prosperico Ventures, a Shanghai-based venture capital fund, co-led the funding round in Singlera. New and existing investors, including UCF Medical Investment, and Jointown Pharmaceutical Group, also joined the latest fundraising.
In a statement, Singlera said it will use the funds to expand the development and commercialization of its non-invasive genetic tests for early-stage cancer detection and clinical validation studies.
&#8220;Singlera will also use the funds to further expand its research facilities and its TiTanSeq and MONOD platforms into new product lines that address early cancer detection, diagnosis, and personalized treatment,&#8221; the company added.
TiTanSeq and MONOD could substantially enhance the accuracy of cancer detection at early stages and significantly improve patients&#8217; survival chances, Yuan Gao, chairman of Singlera Genomics, said.
Gao, who is a professor at Johns Hopkins University, co-founded the company with Professor Kun Zhang from University of California, Jiangli Zhang, Qiang Liu and Dr Rui Liu in July 2014.
The company said it has also made progress on applying high-throughput sequencing of methylated circulating tumour DNA to detecting and diagnosing early-stage cancer.
“Singlera is striving to improve clinical outcomes for cancer patients through early-stage detection and accurate and informative cancer diagnoses,” it said in a statement.
With operation centres in the US and China, Singlera Genomics also provides customized sequencing services to pharmaceutical companies and medical research institutions.
Commenting on the investment, Green Pine Venture Partners managing partner Luo Fei said Greenpine will support Singlera as it continues to strive in the field of early-stage cancer detection.
&#8220;Singlera is working to change the paradigm of cancer detection and may lead to important advances in oncology,&#8221; he said.
Shenzhen-based Green Pine Capital was established in 2007 and has been an active investor in early- to high growth-stage innovative enterprises.
Also Read:
<a style="color: #ff0000;" href="https://www.dealstreetasia.com/stories/chinese-vc-lilly-asia-leads-20m-series-round-genetic-testing-firm-singlera-51419/">Chinese VC Lilly Asia leads $20m Series A round in genetic testing firm Singlera</a>
<a style="color: #ff0000;" href="https://www.dealstreetasia.com/stories/bill-gates-chinas-tencent-backed-cancer-detection-firm-grail-plans-hk-ipo-93337/">Bill Gates, China’s Tencent-backed cancer detection firm Grail plans HK IPO</a>

US and Shanghai-based non-invasive genetic diagnostic firm Singlera Genomics has raised $60 million in a round co-led by Green Pine Capital and Prosperico Ventures.

Chinese VCs Green Pine, Lilly Asia back Singlera's $60m Series A

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Chinese VCs Green Pine, Lilly Asia back Singlera's $60m Series A

Start your deal-making journey now!

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief